Valuation: Lundbeck

Market Cap 40.51B 6.17B 5.41B 5B 4.68B 8.75B 582B 8.95B 59.99B 23.22B 287B 23.17B 22.66B 998B P/E 2026 *
9.32x
P/E 2027 * 9.12x
Enterprise Value 44.61B 6.8B 5.96B 5.5B 5.15B 9.64B 641B 9.86B 66.06B 25.57B 316B 25.51B 24.95B 1,099B EV / Sales 2026 *
1.74x
EV / Sales 2027 * 1.57x
Free-Float
30.76%
Yield 2026 *
3.51%
Yield 2027 * 3.59%
1 day-1.66%
1 week+1.71%
Current month-2.84%
1 month-1.14%
3 months+9.09%
6 months-2.59%
Current year-2.34%
1 week 5.55
Extreme 5.55
5.76
1 month 5.54
Extreme 5.545
6.03
Current year 4.85
Extreme 4.852
6.26
1 year 4.48
Extreme 4.476
6.4
3 years 3.67
Extreme 3.666
6.62
5 years 3.26
Extreme 3.259
8.85
10 years 3.26
Extreme 3.259
8.85
Manager TitleAgeSince
Chief Executive Officer 59 01/10/2023
Director of Finance/CFO 49 01/09/2022
Chief Tech/Sci/R&D Officer 67 01/03/2019
Director TitleAgeSince
Director/Board Member 66 25/03/2015
Chairman 57 26/03/2025
Director/Board Member 67 25/03/2015
Change 5-day change 1-year change 3-year change Capi.($)
-1.66%+1.71% - - 6.18B
-0.04%+1.72%+5.20%+84.10% 89.39B
+1.35%+7.28%+42.31%+155.58% 55.72B
-1.07%+0.36%-6.10%+237.80% 22B
-3.11%-3.90%-13.86%-27.43% 7.63B
-5.31%-6.81%-34.61%-37.49% 6.81B
-1.19%-3.60%-15.29%-33.23% 6.28B
-0.23%+1.72%-0.75%+21.40% 5.28B
-4.35%-4.35%-9.77%-16.90% 3.39B
+0.50%+1.31%+12.88%+11.32% 3.32B
Average -1.51%-0.95%-2.22%+43.91% 22.2B
Weighted average by Cap. -0.21%+1.91%+11.29%+104.28%

Financials

2026 *2027 *
Net sales 25.7B 3.92B 3.44B 3.17B 2.97B 5.55B 370B 5.68B 38.06B 14.73B 182B 14.7B 14.38B 633B 25.74B 3.92B 3.44B 3.18B 2.97B 5.56B 370B 5.69B 38.11B 14.75B 182B 14.72B 14.4B 634B
Net income 4.71B 718M 630M 581M 544M 1.02B 67.72B 1.04B 6.98B 2.7B 33.4B 2.69B 2.63B 116B 4.81B 732M 643M 593M 555M 1.04B 69.11B 1.06B 7.12B 2.76B 34.09B 2.75B 2.69B 118B
Net Debt 4.1B 624M 548M 506M 473M 885M 58.92B 906M 6.07B 2.35B 29.06B 2.34B 2.29B 101B -30.08M -4.58M -4.02M -3.71M -3.47M -6.5M -432M -6.65M -44.54M -17.24M -213M -17.2M -16.83M -741M
Logo Lundbeck
H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia. Its product portfolio includes: Cipralex for the treatment of depression and anxiety disorders, Ebixa for the treatment of Alzheimer’s disease, Azilect for the treatment of Parkinson’s disease, Xenazine for the treatment of Huntington’s disease and Sabril for the treatment of epilepsy, among others. The Company operates through a number of subsidiaries, such as Lundbeck SAS, Lundbeck GmbH, SIA Lundbeck Latvia and Lundbeck LLC.
Employees
5,000
Date Price Change
26/06/26 €5.640 -1.66%
25/06/26 €5.735 -0.09%
24/06/26 €5.740 -0.43%
23/06/26 €5.765 +3.13%
22/06/26 €5.590 +0.81%
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
42.00DKK
Average target price
47.21DKK
Spread / Average Target
+12.40%

Quarterly revenue - Rate of surprise